To address the underlying mechanisms implicated in this response and the target “location” of the therapy, we used IHC to analyze human PD-1 and PD-L1 expression, with the aim of identifying the anti-PD-1 target and its ligand in treated and untreated tumor samples. This evidence concerns the gene PDCD1 and neoplasm.